Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $200

Benzinga Newsdesk www.benzinga.com Positive 92.6%

Neg 0% Neu 0% Pos 92.6%

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $140 to $200.